For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 11 results
Author Title [ Type(Asc)] Year
Filters: Author is Lin, Gang  [Clear All Filters]
Journal Article
Santos Rde Luna Al, Bai L, Singh PK, Murakami N, Fan H, Zhan W, Zhu Y, Jiang X, Zhang K, Assker JPierre et al..  2017.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.. Nat Commun. 8(1):1692.
Vaubourgeix J, Lin G, Dhar N, Chenouard N, Jiang X, Botella H, Lupoli T, Mariani O, Yang G, Ouerfelli O et al..  2015.  Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells.. Cell Host Microbe. 17(2):178-90.
Zhan W, Hsu H-C, Morgan T, Ouellette T, Burns-Huang K, Hara R, Wright AG, Imaeda T, Okamoto R, Sato K et al..  2019.  Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.. J Med Chem. 62(20):9246-9253.
Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, Cao H, Popescu C, Gurney M, Hotha S et al..  2008.  Selective killing of nonreplicating mycobacteria.. Cell Host Microbe. 3(3):137-45.
Totaro KA, Barthelme D, Simpson PT, Jiang X, Lin G, Nathan C, Sauer RT, Sello JK.  2017.  Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.. ACS Infect Dis. 3(2):176-181.
Lin G, Chidawanyika T, Tsu C, Warrier T, Vaubourgeix J, Blackburn C, Gigstad K, Sintchak M, Dick L, Nathan C.  2013.  N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.. J Am Chem Soc. 135(27):9968-71.
Zhan W, Visone J, Ouellette T, Harris JC, Wang R, Zhang H, Singh PK, Ginn J, Sukenick G, Wong T-T et al..  2019.  Improvement of Asparagine Ethylenediamines as Anti-malarial -Selective Proteasome Inhibitors.. J Med Chem. 62(13):6137-6145.
Moallemian R, Rehman AUr, Zhao N, Wang H, Chen H, Lin G, Ma X, Yu J.  2020.  Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation.. Biochem Pharmacol. 177:113964.
Karreci ESula, Fan H, Uehara M, Mihali AB, Singh PK, Kurdi AT, Solhjou Z, Riella LV, Ghobrial I, Laragione T et al..  2016.  Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice.. Proc Natl Acad Sci U S A. 113(52):E8425-E8432.
Kirkman LA, Zhan W, Visone J, Dziedziech A, Singh PK, Fan H, Tong X, Bruzual I, Hara R, Kawasaki M et al..  2018.  Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance.. Proc Natl Acad Sci U S A. 115(29):E6863-E6870.
Vanheer LN, Zhang H, Lin G, Kafsack BFC.  2020.  Activity of Epigenetic Inhibitors against Plasmodium falciparum Asexual and Sexual Blood Stages.. Antimicrob Agents Chemother. 64(7)